Walleye Capital LLC Has $280,000 Stock Position in BrainsWay Ltd. (NASDAQ:BWAY)

Walleye Capital LLC reduced its holdings in shares of BrainsWay Ltd. (NASDAQ:BWAY) by 48.7% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 30,253 shares of the company’s stock after selling 28,748 shares during the quarter. Walleye Capital LLC owned 0.18% of BrainsWay worth $280,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Rhumbline Advisers raised its position in shares of BrainsWay by 10.3% during the second quarter. Rhumbline Advisers now owns 18,077 shares of the company’s stock worth $110,000 after acquiring an additional 1,695 shares during the last quarter. Perritt Capital Management Inc bought a new stake in shares of BrainsWay in the second quarter valued at $121,000. Good Life Advisors LLC raised its stake in shares of BrainsWay by 65.5% in the third quarter. Good Life Advisors LLC now owns 55,800 shares of the company’s stock valued at $516,000 after buying an additional 22,080 shares during the period. Finally, Acadian Asset Management LLC raised its stake in shares of BrainsWay by 48.1% in the second quarter. Acadian Asset Management LLC now owns 259,787 shares of the company’s stock valued at $1,567,000 after buying an additional 84,371 shares during the period. 30.11% of the stock is currently owned by institutional investors.

BrainsWay Stock Performance

BWAY stock opened at $10.04 on Wednesday. BrainsWay Ltd. has a fifty-two week low of $4.61 and a fifty-two week high of $10.98. The business’s 50 day moving average price is $9.86 and its two-hundred day moving average price is $8.05. The company has a market capitalization of $167.47 million, a price-to-earnings ratio of 100.41 and a beta of 1.23.

BrainsWay (NASDAQ:BWAY) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.03. BrainsWay had a return on equity of 3.52% and a net margin of 3.88%. The company had revenue of $10.50 million for the quarter, compared to the consensus estimate of $10.07 million. During the same quarter in the prior year, the business posted ($0.01) EPS. Sell-side analysts forecast that BrainsWay Ltd. will post 0.06 earnings per share for the current year.

Analyst Ratings Changes

BWAY has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of BrainsWay in a research report on Monday, October 21st. Northland Securities boosted their target price on BrainsWay from $11.00 to $12.50 and gave the company an “outperform” rating in a research note on Thursday, October 3rd.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.